Point of Care Diagnostics Market Overview Analysis By Fortune Business Insights

Market Summary

According to Fortune Business Insights: The global point of care (POC) diagnostics market was valued at USD 32.87 billion in 2025 and is projected to grow from USD 34.47 billion in 2026 to USD 60.43 billion by 2034, at a CAGR of 7.27% during the forecast period. Point of care testing (POCT) refers to diagnostic testing conducted at or near the site of patient care, enabling rapid, accurate disease detection with minimal turnaround time compared to central laboratory testing. The market spans blood glucose monitoring, infectious disease testing, cardiometabolic disease testing, pregnancy and fertility testing, and hematology testing, deployed across hospital bedsides, physician offices, urgent care clinics, and home settings. North America dominated the market with a 35.60% share in 2025, valued at USD 11.69 billion.

Get a Sample Research PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/101072

Key Market Drivers

The increasing adoption of multiplex POC platforms due to rapid turnaround time and high sensitivity is the primary market driver. Multiplex testing technology enables simultaneous identification and detection of multiple pathogens or biomarkers from a single sample, substantially reducing testing time while enhancing diagnostic accuracy. Healthcare facilities — particularly those with resource limitations — are increasingly deploying these platforms to manage multiple disease burdens efficiently. In June 2025, researchers at NYU Abu Dhabi announced a breakthrough paper-based diagnostic device capable of detecting infectious diseases including COVID-19 in under ten minutes, offering an affordable and rapid solution for on-site infectious disease screening. Multiplex diagnostics also generate considerable economic benefits by reducing sample processing costs, operational overhead, and resource requirements, while aligning with global healthcare decentralization initiatives.

Rising prevalence of chronic and infectious diseases is a reinforcing structural driver. The CDC reported that diabetes prevalence grew by an estimated 3.6% in the U.S. from 2021 to 2023, expanding the patient population requiring regular blood glucose monitoring. According to CDC data, approximately 35.5 million U.S. adults are estimated to have Chronic Kidney Disease — representing one in seven adults — driving demand for urine-based POC tests. The growing burden of HIV, sexually transmitted infections, cardiovascular conditions, and respiratory diseases further sustains broad-based demand across multiple POC testing categories.

CRISPR-based POC diagnostic tools represent an important emerging market trend. These technologies offer speed, specificity, and ease of use that significantly improve upon traditional nucleic acid amplification methods, enabling rapid pathogen identification with high sensitivity and minimal sample preparation — making them well suited for POC settings. In August 2023, CrisprBits announced a strategic collaboration with Molbio Diagnostics to identify and commercialize CRISPR-based POC diagnostics, reflecting growing commercial momentum for next-generation diagnostic platforms.

Market Restraints and Challenges

Challenges associated with result consistency and reliability are the primary market restraints. Despite significant technological advancements, variability in test performance across different platforms — arising from calibration issues, operator errors, and inadequate quality controls — can deter adoption and limit clinical trust, particularly in smaller healthcare facilities lacking extensive quality control infrastructure. Variation in regulatory compliance across geographies compounds this challenge: manufacturers must navigate distinct standards and approval processes from the FDA, EMA, CFDA, and other bodies across each target market, increasing production timelines, compliance costs, and barriers to global expansion. Rapid changes in regulatory requirements following public health crises add further complexity, disproportionately affecting smaller market participants with limited regulatory resources.

Market Opportunities

The expansion of connected and remote patient monitoring via IoT integration represents the most significant market opportunity. IoT-enabled POC diagnostic platforms facilitate seamless data transfer from testing devices to electronic health records and cloud-based platforms, enabling real-time patient monitoring, analytics, and remote patient management. These connected solutions empower telehealth services by providing reliable patient data remotely — particularly beneficial in rural and underserved regions with limited healthcare infrastructure. In April 2025, binx health announced a strategic partnership with WellStreet Urgent Care to improve patient access to sexually transmitted infection treatment and advanced POC technologies across WellStreet care locations using its binx.io platform, illustrating the growing commercial value of connected POC solutions.

Segmentation Analysis

By product, the blood glucose monitoring segment is expected to account for 54.93% of the market in 2026, anchored by rising diabetes prevalence and continuous innovation in glucose monitoring technology. In February 2024, Dexcom launched Dexcom ONE+, its latest continuous glucose monitoring (CGM) system in the Netherlands, demonstrating active product development in this segment. Pregnancy and fertility testing is projected to expand at a significant rate, driven by rising fertility issues, growing awareness of sexual health, and increasing product adoption in the U.S., Germany, and the U.K. Infectious disease testing, hematology testing, and cardiometabolic disease testing segments are all growing in parallel, supported by rising chronic disease prevalence and higher rates of screening and early diagnosis.

By sample type, the blood segment is expected to hold a dominant 77.05% share in 2026, reflecting the broad clinical utility of blood tests for diagnosing HIV/AIDS, cardiovascular conditions, and organ function disorders. The urine segment is expected to grow at a significant CAGR, driven by the rising prevalence of chronic kidney disease and urological disorders requiring regular diagnostic monitoring.

By end user, the hospital bedside segment is projected to lead with a 40.50% share in 2026, driven by rising adoption of advanced POC testing devices in hospitals, improving healthcare infrastructure, and growing public and private sector healthcare investment. The urgent care and retail clinics segment is expected to register the highest CAGR, as patients increasingly shift from primary care centers to urgent care settings and the number of urgent care centers expands — with approximately 14,075 operational in the U.S. by end of 2022, representing 22.6% growth since 2019, according to the Urgent Care Association. The home and self-testing segment is growing steadily, supported by rising patient adoption of home test kits and a growing number of product launches targeting self-testing convenience.

Regional Outlook

North America leads the global market at USD 11.69 billion in 2025, projected at USD 12.29 billion in 2026, driven by high POC diagnostic penetration, a favorable reimbursement landscape, and a strong FDA product approval pipeline. The U.S. market alone is valued at USD 10.7 billion in 2026, supported by intensive R&D investment and a dense network of POC technology developers. Europe contributed USD 10.56 billion in 2025 (32.10% global share), projected at USD 11.04 billion in 2026, with Germany at USD 2.46 billion and the U.K. at USD 2.23 billion — both markets benefiting from active rapid diagnostic product launches and strong healthcare infrastructure. Asia Pacific reached USD 6.35 billion in 2025 (19.30% share), projected at USD 6.63 billion in 2026, driven by rising infectious disease and chronic ailment prevalence. India leads regional growth at USD 1.87 billion in 2026, with China at USD 1.43 billion and Japan at USD 1.42 billion. Latin America generated USD 3.11 billion in 2025 (9.50% share), with strong CAGR growth driven by rising healthcare expenditure and chronic disease burden. The Middle East and Africa contributed USD 1.17 billion in 2025, growing steadily on the back of new product launches — including the June 2025 extension of the PMcardio and Alphaiota partnership to introduce the first AI-powered heart attack diagnostic solution in Saudi Arabia.

Connect with Our Expert for any Queries: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/101072

Competitive Landscape

The global POC diagnostics market is semi-consolidated, with a few prominent players accounting for the majority of market share alongside a growing number of innovative new entrants. Key players include F. Hoffmann-La Roche Ltd. (Switzerland), Abbott (U.S.), EKF Diagnostics Holdings plc (U.K.), Cardinal Health Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Quest Diagnostics Incorporated (U.S.), BD (U.S.), bioMérieux SA (France), QuidelOrtho Corporation (U.S.), and Bio-Rad Laboratories Inc. (U.S.). In November 2024, NOWDiagnostics launched the first U.S. home syphilis test providing results in 15 minutes, now available across all 50 states. In July 2024, F. Hoffmann-La Roche received CE approval for its AI-enabled blood glucose monitoring system capable of predicting critical healthcare issues in diabetic populations. In February 2023, bioMérieux received FDA approval for its BIOFIRE SPOTFIRE respiratory panel system, expanding its POC testing portfolio. In January 2023, Cipla Limited launched Cippoint, a POC device offering testing for both non-communicable and infectious diseases across multiple health conditions.

Curious About Japan’s Market? Explore the Latest - Point of Care Diagnostics Market - Insights